Last reviewed 2026-05-26 · How we verify

YS5 antibody

Robert Flavell, MD, PhD · Phase 1 active Biologic ✓ Verified May 2026

YS5 antibody is a Biologic drug developed by Robert Flavell, MD, PhD. It is currently in Phase 1 development. Also known as: YS5, Unmodified YS5 antibody.

The YS5 antibody is being studied in clinical trials for Prostate Cancer and Metastatic Castration-resistant Prostate Cancer. The YS5 antibody targets Disialoganglioside GD2, a molecular target identified by ChEMBL.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	YS5 antibody
Also known as	YS5, Unmodified YS5 antibody
Sponsor	Robert Flavell, MD, PhD
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

YS5 antibody CI brief — competitive landscape report
YS5 antibody updates RSS · CI watch RSS
Robert Flavell, MD, PhD portfolio CI

Frequently asked questions about YS5 antibody

What is YS5 antibody?

YS5 antibody is a Biologic drug developed by Robert Flavell, MD, PhD.

Who makes YS5 antibody?

YS5 antibody is developed by Robert Flavell, MD, PhD (see full Robert Flavell, MD, PhD pipeline at /company/robert-flavell-md-phd).

Is YS5 antibody also known as anything else?

YS5 antibody is also known as YS5, Unmodified YS5 antibody.

What development phase is YS5 antibody in?

YS5 antibody is in Phase 1.

Manufacturer: Robert Flavell, MD, PhD — full pipeline
Also known as: YS5, Unmodified YS5 antibody

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing